- Scribe secures $129M in a rare gene editing IPOThe startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.BioPharma Dive · 4d ago↗ source
- FDA panel endorses broader use of certain peptidesIn a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supportin…BioPharma Dive · 5d ago↗ source
- This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and moreWelcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This we…